We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+36.02%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$334M
AUM Growth
+$107M
Cap. Flow
+$48M
Cap. Flow %
14.36%
Top 10 Hldgs %
34.01%
Holding
80
New
29
Increased
13
Reduced
13
Closed
20

Top Buys

Rank Stock Value
1
LHCG
LHC Group LLC
LHCG
+$11M
2
CRL icon
Charles River Laboratories
CRL
+$8.78M
3
COR icon
Cencora
COR
+$8.29M
4
NUVA
NuVasive, Inc.
NUVA
+$7.23M
5
MOH icon
Molina Healthcare
MOH
+$6.81M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$10.4M
2
CNC icon
Centene
CNC
+$10.1M
3
EHC icon
Encompass Health
EHC
+$7.36M
4
MASI
Masimo
MASI
+$6.2M
5
NVS icon
Novartis
NVS
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 86.88%
2 Energy 6.53%
3 Technology 0.84%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$325B
$5.8M 1.74%
78,600
-57,640
-42% -$4.34M
LLY icon
27
Eli Lilly
LLY
$1.1T
$5.75M 1.72%
+35,000
New +$5.37M
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.71M 1.71%
50,000
+10,000
+25% +$970K
MNTA
29
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.99M 1.49%
+150,000
New +$4.78M
EXAS
30
DELISTED
Exact Sciences
EXAS
$4.78M 1.43%
55,000
-25,000
-31% -$2M
ABT icon
31
Abbott
ABT
$190B
$4.57M 1.37%
50,000
+5,000
+11% +$452K
HZNP
32
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.45M 1.33%
+80,000
New +$3.42M
BAX icon
33
Baxter International
BAX
$14.4B
$4.3M 1.29%
+50,000
New +$4.36M
ZBH icon
34
Zimmer Biomet
ZBH
$18.6B
$4.18M 1.25%
+36,050
New +$4.15M
MCK icon
35
McKesson
MCK
$105B
$3.84M 1.15%
25,000
– –
NVST icon
36
Envista
NVST
$4.53B
$3.69M 1.11%
+175,000
New +$3.28M
HALO icon
37
Halozyme
HALO
$11.6B
$3.62M 1.08%
135,000
+85,000
+170% +$1.92M
EXEL icon
38
Exelixis
EXEL
$13.2B
$3.56M 1.07%
150,000
– –
GOSS icon
39
Gossamer Bio
GOSS
$86.2M
$3.51M 1.05%
+270,000
New +$3.4M
PODD icon
40
Insulet
PODD
$9.88B
$3.5M 1.05%
+18,000
New +$3.44M
AKBA icon
41
Akebia Therapeutics
AKBA
$238M
$3.4M 1.02%
250,000
+50,000
+25% +$517K
MRNA icon
42
PUT
Moderna
MRNA
$24B
$3.21M 0.96%
+50,000
New +$2.74M
DNLI icon
43
Denali Therapeutics
DNLI
$4B
$3.14M 0.94%
130,000
+40,000
+44% +$940K
RVTY icon
44
Revvity
RVTY
$12.9B
$2.94M 0.88%
30,000
-15,000
-33% -$1.37M
CHNG
45
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$2.8M 0.84%
+250,000
New +$2.81M
DRNA
46
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.79M 0.84%
110,000
-75,000
-41% -$1.62M
ITCI
47
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.57M 0.77%
+100,000
New +$2.02M
ABBV icon
48
AbbVie
ABBV
$440B
$2.46M 0.74%
+25,000
New +$2.2M
NBIX icon
49
Neurocrine Biosciences
NBIX
$16.6B
$2.44M 0.73%
+20,000
New +$2.21M
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
$2.43M 0.73%
+90,000
New +$2.48M
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Integral Health Asset Management held 80 positions worth $334M, up 47% from $227M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Integral Health Asset Management deployed $48M of net new capital in Q2 2020, opening 29 new positions and adding to 13 existing holdings. Its largest new stake was Charles River Laboratories: 55,000 shares worth $9.59M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was Merck, an estimated $4.34M trimmed.

  • Integral Health Asset Management's largest Q2 2020 buy was Charles River Laboratories: 55,000 shares worth $9.59M.
  • Integral Health Asset Management added most to LHC Group LLC in Q2 2020, an estimated $11M increase.
  • Integral Health Asset Management's biggest Q2 2020 reduction was Merck, cutting an estimated $4.34M.
  • Integral Health Asset Management fully exited Medtronic in Q2 2020, selling an estimated $10.4M.
  • Integral Health Asset Management's ten largest holdings make up 34% of its $334M portfolio in Q2 2020.
  • Integral Health Asset Management opened 29 new positions and closed 20 in Q2 2020.
  • Integral Health Asset Management's portfolio value rose 47% quarter-over-quarter to $334M.

Based on Integral Health Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.